Multicenter validation of an assay to predict anti-PD-1 disease control in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma: The PREDAPT Study

Kevin C. Flanagan, Jon Earls, Jeffrey Hiken, Rachel L. Wellinghoff, Michelle M. Ponder, Howard L. Mcleod, William H. Westra, Vera Vavinskaya, Leisa Sutton, Ida Deichaite, Orlan K. Macdonald, Karim Welaya, James L. Wade III, Georges Azzi, Andrew W. Pippas, Jennifer Slim, Bruce Bank, Xingwei Sui, Steven E. Kossman, Todd D. Shenkenberg, Warren L. Alexander, Katharine A Price, Jessica Ley, David N. Messina, Jarret I. Glasscock, A. Dimitrios Colevas, Ezra E.W. Cohen, Douglas R. Adkins, Eric J. Duncavage
doi: https://doi.org/10.1101/2024.05.31.24308285

Data Availability

The data underlying this study, including anonymized patient-level OncoPrism-HNSCC, PD-L1, and TMB measurements, are available for non-commercial use from the corresponding author upon reasonable request.

Back to top
Posted June 01, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Multicenter validation of an assay to predict anti-PD-1 disease control in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma: The PREDAPT Study
Kevin C. Flanagan, Jon Earls, Jeffrey Hiken, Rachel L. Wellinghoff, Michelle M. Ponder, Howard L. Mcleod, William H. Westra, Vera Vavinskaya, Leisa Sutton, Ida Deichaite, Orlan K. Macdonald, Karim Welaya, James L. Wade III, Georges Azzi, Andrew W. Pippas, Jennifer Slim, Bruce Bank, Xingwei Sui, Steven E. Kossman, Todd D. Shenkenberg, Warren L. Alexander, Katharine A Price, Jessica Ley, David N. Messina, Jarret I. Glasscock, A. Dimitrios Colevas, Ezra E.W. Cohen, Douglas R. Adkins, Eric J. Duncavage
medRxiv 2024.05.31.24308285; doi: https://doi.org/10.1101/2024.05.31.24308285
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area